How to reconstitute CJC-1295 with DAC: mixing and storage
An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
Also called: CJC-1295 DAC, DAC:GRF, DAC-GRF.
GHRH analogues · Long-acting GHRH receptor agonist with an albumin-binding tag.
Comes as: Freeze-dried powder vial; no approved CJC injection product..
Mixed with: Community reports use bacteriostatic water; no approved CJC diluent or home-mixing instruction exists..
Common vial sizes: 2 mg. Common water amounts: 1, 2 mL.
- A cited post discusses 2 mg with 1 mL; another suggests 2 mL. These are reports, not validated formulations.
- DAC and ipamorelin have different exposure profiles. A fixed blend prevents independent adjustment.
- Water volume changes concentration, not milligrams. Do not copy syringe units from a different vial.
- Bacteriostatic water does not sterilize contaminated powder. Clear appearance cannot establish sterility.
Before mixing: Supplier reports summarized by FDA describe −20°C powder storage. No approved consumer storage schedule exists.
After mixing: Reports summarized by FDA describe about 4°C. No validated beyond-use date for community mixtures was found.
Related to CJC-1295 with DAC
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
- Anticoagulant medicines - Side effects, NHS
- DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed
- Know When to Go to the ER, American College of Emergency Physicians · American College of Emergency Physicians
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.